Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289481 · ClinicalTrials.gov registry record · Early Phase 1
Treatment of HFpEF With Nitrate Supplement
A Early Phase 1 study of Heart Failure With Normal Ejection Fraction, sponsored by MaineHealth.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03289481: Completed Early Phase 1 study of Heart Failure With Normal Ejection Fraction, sponsored by MaineHealth.
NCT03289481 is a Early Phase 1 study of Heart Failure With Normal Ejection Fraction that has completed, run by MaineHealth. The registered enrollment target is 13 participants, below the 638-participant average among 10 other Heart Failure With Normal Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289481, a Early Phase 1 study of Heart Failure With Normal Ejection Fraction, has completed, sponsored by MaineHealth.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
Primary Outcome
change in total time traveled on treadmill
Conditions Studied
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT Active lozenge
Study Locations (1)
Maine
- Penobscot Bay Medical Center - Rockport
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-06-29 |
| Est. Completion | 2018-08-22 |
| Phase | Early Phase 1 |
What the finished NCT03289481 record still lists
NCT03289481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 638-participant average among 10 other Heart Failure With Normal Ejection Fraction trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Heart Failure With Normal Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03289481 reports a single indexed study location in Maine.
Frequently Asked Questions
What is clinical trial NCT03289481 about?
NCT03289481 is a clinical study titled "Treatment of HFpEF With Nitrate Supplement". The objective of this project is to determine if Neo40, a nitric oxide generating lozenge, when consumed twice daily by subjects with HFpEF, will increase exercise tolerance, decrease symptoms and improve quality of life for patients.
What is the current status of trial NCT03289481?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2017-06-29. Estimated completion is 2018-08-22.
What conditions does trial NCT03289481 study?
This clinical trial studies the following conditions: Heart Failure With Normal Ejection Fraction.
What interventions are being tested in trial NCT03289481?
The interventions under investigation include: Placebo (DRUG), Active lozenge (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03289481?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03289481 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Normal Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03289481's enrollment target sits among peer trials
13 11th of 10 the lowest of 10 other Heart Failure With Normal Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Normal Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise Intolerance in Heart Failure
RECRUITING
-
New Orleans Pulmonary Hypertension Biobank
RECRUITING
-
Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure
RECRUITING
-
Imaging Histone Deacetylase in the Heart
RECRUITING · NA
-
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
ACTIVE NOT RECRUITING · NA
-
Circulating RNAs in Acute Congestive Heart Failure
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI